HealthInvest Partners AB Acquires Shares of 42,820 Pfizer Inc. (NYSE:PFE)

HealthInvest Partners AB bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 42,820 shares of the biopharmaceutical company's stock, valued at approximately $1,233,000. Pfizer makes up about 1.0% of HealthInvest Partners AB's investment portfolio, making the stock its 25th biggest position.

A number of other hedge funds also recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. grew its stake in shares of Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company's stock worth $157,215,000 after buying an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $255,000. Brookstone Capital Management boosted its position in Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company's stock worth $14,109,000 after buying an additional 212,369 shares during the period. ETF Store Inc. lifted its holdings in shares of Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company's stock worth $214,000 after purchasing an additional 727 shares during the period. Finally, Farmers Trust Co. grew its position in shares of Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company's stock valued at $6,503,000 after buying an additional 4,410 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock traded down $0.22 during trading on Tuesday, hitting $25.69. The company's stock had a trading volume of 28,601,821 shares, compared to its average volume of 42,553,457. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market cap of $145.47 billion, a PE ratio of 71.69, a P/E/G ratio of 1.16 and a beta of 0.61. The business has a fifty day moving average of $27.27 and a 200-day moving average of $28.84. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $41.33.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business's revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.14 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Monday. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target on the stock. Argus lowered Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Finally, TD Cowen cut Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.